L&G Pharma Breakthrough UCITS ETF (EUR) | ETLIRekisteröidy nähdäksesi ratingit |
Rahaston kehitys | 31.03.2024 |
1000 euron arvon kehitys (EUR) | Tarkempi kaavio |
Rahasto | 15,4 | 5,0 | -2,9 | -12,6 | -4,2 | |
+/- Luokka | -3,9 | 8,0 | 9,9 | -13,7 | -7,9 | |
+/- Ind. | -10,5 | -1,9 | 0,1 | -22,5 | -14,2 | |
Luokka: Sektori bioteknologia osakkeet | ||||||
Luokan vertailuindeksi: Morningstar Gbl Biotechnolo... |
Yleiskatsaus | ||
Lopetushinta 26.04.2024 | EUR 8,67 | |
1 pv muutos | 1,58% | |
Morningstar rahastoluokka™ | Sektori bioteknologia osakkeet | |
Volume | 1125 | |
Exchange | DEUTSCHER KASSENVEREIN AG GRUPPE DEUTSCHE BOERSE | |
ISIN | IE00BF0H7608 | |
Rahaston koko (Mil) 26.04.2024 | USD 17,92 | |
Rahastosarjan koko (Mil) 26.04.2024 | USD 17,92 | |
Juoksevat kulut 14.02.2024 | 0,49% |
Sijoituspolitiikka: L&G Pharma Breakthrough UCITS ETF (EUR) | ETLI |
The investment objective of the Fund is to provide exposure to bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. In order to achieve this investment objective, the Fund will seek to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”). It will do so by investing primarily in a portfolio of equity securities that, as far as possible and practicable, consists of the component securities of the Index in similar proportions to their weightings in the Index and may have exposure to or invest directly up to 20% of its Net Asset Value in shares issued by the same body, which limit may be raised to 35% for a single issuer in exceptional market conditions, including (but not limited to) circumstances in which such issuer occupies a dominant market position. |
Tuotto | |||||||||||||
|
Hallinnointi | ||
Salkunhoitaja Salkunhoitajana alkaen | ||
- - | ||
Perustamispäivä 18.01.2018 |
Mainos |
Luokan vertailuindeksi | |
Rahaston vertailuindeksi | Morningstar-vertailuindeksi |
Solactive Pharma Breakthrough V NR USD | Morningstar Gbl Biotechnology NR USD |
Kohdemarkkina | ||||||||||||||||||||
|
Rahastosalkun sisältö L&G Pharma Breakthrough UCITS ETF (EUR) | ETLI | 26.04.2024 |
|
|
5 suurinta sijoitusta | Sektori | % |
SciClone Pharmaceuticals (Holdin... | Terveydenhuolto | 3,39 |
AstraZeneca PLC ADR | Terveydenhuolto | 2,91 |
Ipsen SA | Terveydenhuolto | 2,75 |
Merck & Co Inc | Terveydenhuolto | 2,59 |
Swedish Orphan Biovitrum AB | Terveydenhuolto | 2,54 |
Nousu Lasku Uusi salkussa | ||
L&G Pharma Breakthrough UCITS ETF (EUR) | ETLI |